GET DAILY SIGNALSImmunityBio (IBRX) Q3 2026 Earnings Preview: Tracking ANKTIVA Revenue Momentum
Key Takeaways
- ImmunityBio is expected to report third-quarter 2026 results around November 5, 2026, with consensus pointing to a loss of about $0.08 per share on roughly $58.1 million in revenue.
- The report follows eight consecutive quarters of sequential growth in net product revenue for ANKTIVA, its sole marketed drug, which reached a record $50.7 million in Q2 2026.
- Investors will be watching whether commercial demand can keep pace with the consensus top line and whether management updates its outlook on label-expansion milestones.
- A key regulatory catalyst sits just ahead: the FDA's January 6, 2027 decision on the company's application to expand ANKTIVA's bladder-cancer label.
- You can get more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages, and we invite you to explore them.
- Explore Trending AI Robots to discover AI-driven trading strategies built for changing market conditions.
Why These Earnings Matter
ImmunityBio, Inc. (IBRX) operates as a commercial-stage biotechnology company centered on ANKTIVA, an immunotherapy designed to activate the immune system against cancer and infectious diseases. Its quarterly results now serve as a direct gauge of how rapidly ANKTIVA is gaining traction among urologists, given that the drug drives nearly all reported revenue. The company has posted eight straight quarters of sequential product-revenue growth, an uncommon pattern for a recently launched oncology treatment. With revenue climbing sharply yet losses staying sizable, each report checks whether commercial progress can narrow the path to profitability. In my view, the Q3 2026 release carries added weight because it lands just before a major regulatory decision that could broaden the drug's market reach.
What Analysts Expect
Analysts anticipate ImmunityBio will post a loss of roughly $0.08 per share alongside revenue of about $58.1 million for the third quarter of 2026, based on consensus estimates. This follows adjusted losses of $0.08 per share and total revenue of $51.2 million in Q2 2026, when net product revenue from ANKTIVA rose 92% year over year to a record $50.7 million. I also checked this using Tickeron’s AI Screener to compare the setup with other biotech names. Investors should distinguish between GAAP and non-GAAP figures. In Q2 2026, the GAAP net loss attributable to common stockholders reached $230.4 million, or $0.22 per share, due in part to non-cash changes in fair value tied to a related-party convertible note and warrant liabilities amid the rising stock price. Management’s adjusted (non-GAAP) loss came in at $81.0 million. Beyond the headline numbers, attention will turn to net product revenue growth, gross-to-net pricing, operating expense trends, and the cash position, which stood at $357.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
Market Reaction and Sentiment
Sentiment ahead of the Q3 2026 report stays cautiously optimistic. IBRX shares have advanced strongly year to date, supported by faster ANKTIVA adoption and international regulatory approvals, including marketing authorizations in the United Arab Emirates and a presence now covering roughly 34 countries. At the same time, the stock’s quick rise has magnified non-cash fair-value swings on the convertible-note and warrant liabilities, which can distort the GAAP bottom line. From what I see, investors have generally rewarded steady revenue beats and clear label-expansion progress while reacting more cautiously to any hints of slowing sequential growth. The upcoming print will test whether the stock’s elevated expectations align with continued double-digit sequential gains in product revenue.
Key Factors to Watch Going Forward
The most significant near-term catalyst remains regulatory. The U.S. Food and Drug Administration is reviewing a supplemental Biologics License Application for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease without carcinoma in situ. A decision is due by January 6, 2027, the PDUFA date. BCG refers to Bacillus Calmette-Guérin, the standard immunotherapy for this form of bladder cancer. Management has also indicated plans to file for an additional label expansion in BCG-naïve patients, which would open a substantially larger opportunity. Investors should listen for any updates on that filing timeline during the earnings call. On the commercial front, watch the trajectory of net product revenue along with commentary on pricing, reimbursement, and international rollouts, including Saudi Arabia and Europe. Operating costs merit attention as well: research and development and selling, general, and administrative expenses have risen with the commercial expansion. Finally, balance-sheet strength stays on the radar. The company carries notable liabilities, including a related-party convertible note and a revenue-interest liability, and continues to consume cash. How management addresses future funding needs will likely draw investor focus beyond a single quarter’s revenue figure.
Using Tickeron Tools in My Research
When preparing for earnings like this one, I often turn to Tickeron’s AI Screener to quickly filter biotech peers and spot comparable momentum setups. It helps me cross-check technical patterns, fundamentals, and AI signals without spending hours on manual scans. The tool has become a regular part of how I build context around names like IBRX ahead of key events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IBRX's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for IBRX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 19 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 79 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IBRX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for IBRX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +12.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 210 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.395) is normal, around the industry mean (3.051). P/E Ratio (-8.726) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement